Oncotelic Therapeutics OTLC Estimates

OTC OTLC
$0.02 +0.00 (+0.00%)
At close: Oct 15, 2026 · 4:00 PM EDT
Analyst Estimates

Oncotelic Therapeutics, Inc. Revenue Estimates

Periods 12
Next Period Q4 23
Consensus 0.00

Analysts expect Oncotelic Therapeutics, Inc. to report revenue of 0.00 for Q4 23, against a range of 0.00 to 0.00. The most recent reported quarter, Q3 23, came in at 70,000.00.

Metric Q1 23Q2 23Q3 23Q4 23Q1 24Q2 24Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25
Reported (Actual) 0.000.0070,000.00--------
High Estimate -0.000.000.000.000.000.000.000.000.00-28,189.55
Low Estimate -0.000.000.000.000.000.000.000.000.00-30,250.37
Consensus Estimate -0.000.000.000.000.000.000.000.000.00-29,219.96
Analyst Estimates

Oncotelic Therapeutics, Inc. Earnings Per Share (EPS) Estimates

Periods 12
Next Period Q3 23
Consensus 0.00

Analysts expect Oncotelic Therapeutics, Inc. to report earnings per share of 0.00 for Q3 23, against a range of 0.00 to 0.00. The most recent reported quarter, Q4 25, came in at 0.59.

Metric Q1 23Q2 23Q3 23Q4 23Q1 24Q2 24Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25
Reported (Actual) 0.00-0.02-------0.000.000.59
High Estimate -0.000.000.000.000.000.000.000.000.010.010.00
Low Estimate -0.000.000.000.000.000.000.000.000.010.010.00
Consensus Estimate -0.000.000.000.000.000.000.000.000.010.010.00

Oncotelic Therapeutics, Inc. Estimates API

Pull Wall Street consensus for Oncotelic Therapeutics, Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/estimates?ticker=OTLC&mode=revenue&api_key=YOUR_API_KEY